ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD) from its SEC filings: 2025 revenue $1.1 billion (+12% vs the year before), net margin 36%, free cash flow $105.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $1.1 billion |
| Revenue growth | +12% |
| Net income | $391.0 million |
| Net margin | 36.5% |
| Free cash flow | $105.1 million |
| Diluted EPS | $2.30 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +16% |
| Cash | $385.0 million |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.